Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial

Hypertension Research

Volumn 33, Issue 6, 2010, Pages 600-606

  Nakao, Kazuwa ^a   Hirata, Masakazu ^a   Oba, Koji ^a   Yasuno, Shinji ^a   Ueshima, Kenji ^a   Fujimoto, Akira ^a   Ogihara, Toshio ^b   Saruta, Takao ^c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular diseases; Diabetes; Obesity; Randomized controlled trial

Indexed keywords

AMLODIPINE; CANDESARTAN;

ADULT; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; JAPAN; MALE; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 77953176878     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.38     Document Type: Article

References (20)

1. World Health Organisation, International Association for the Study of Obesity, International Obesity Taskforce. The Asia-Pacific Perspective: Redefining Obesity And Its Treatment. Health Communications Australia, Sydney, 2000.
2. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet 1998; 351: 1755-1762. (Pubitemid 28269185)
4. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trial investigators. N Engl J Med 1999; 340: 677-684.
5. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the captopril prevention project. Diabetes Care 2001; 24: 2091-2096.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus\results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
7. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimskỳ J, Zanchetti A. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405-1412.
8. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T, CASE-J Study Group. Candesartan antihypertensive survival evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979-990.
9. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: CASE-J Trial. Hypertension 2008; 51: 393-398.
10. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
11. Tsugane S, Sasaki S, Tsubono Y. Under-and overweight impact on mortality among middle-aged Japanese men and women: a 10-y follow-up of JPHC study cohort I. Int J Obes (Lond) 2002; 26: 529-537.
12. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48-53.
13. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC, Studies Of Left Ventricular Dysfunction. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD). Circulation 2003; 107: 1291-1296. (Pubitemid 36314413)
14. Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998; 83: 3925-3929.
15. Zorad S, Fickova M, Zelezna B, Macho L, Kral JG. The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen Physiol Biophys 1995; 14: 383-391.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, and Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
17. Miyawaki T, Hirata M, Moriyama K, Sasaki Y, Aono H, Saito N, Nakao K. Metabolic syndrome in Japanese diagnosed with visceral fat measurement by computed tomography. Proc Jpn Acad Ser B 2005; 81: 471.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome\a new world-wide definition. A consensus statement from the international diabetes federation. Diabetes Med 2006; 23: 469-480.
19. National Diabetes Survey. Ministry of health, labour and welfare. Accessed 14 April 2009 at http://www.health-net.or.jp/data/menu05/toukei/tonyo- h14.pdf, 2002.
20. Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: Rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex). Contemp Clin Trials 2009; 30: 97-101.